Header Logo

Connection

Charles Feldman to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Charles Feldman has written about Cost-Benefit Analysis.
Charles Feldman
Connection Strength
0,604
Cost-Benefit Analysis
  1. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults. PLoS One. 2020; 15(1):e0227945.
    View in: PubMed
    Score: 0,604
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.